
CLAIMS

1. A compound of Formula I:



Formula I

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:

V is -C(O)NH- or -NHC(O)-;

T is -NH- or a bond;

⚌ represents a single bond or a double bond;

Y^2 and Y^3 are each independently C or N;

Y^1 and Y^4 are each independently selected from CR^Y, CR^YR^Y, N, NR^Y, O, S, C(O), S(O), and $S(O)_2$;

Y^5 is C or N;

Y^6 and Y^7 are each independently CR^4 or N;

each R^Y is independently selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, and halogen-substituted C_{2-6} alkynyl;

Q is CR^Q or N;

R^Q is selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, halogen-substituted C_{1-6} alkyl, and halogen-substituted C_{1-6} alkoxy;

ring A is 5- to 10-membered heteroaryl, wherein the heteroaryl is optionally substituted with 1, 2, or 3 R^{A1}:

each R^{A1} is independently selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, -C_{0-2} alkylene-OR^{A2}, -C_{0-2} alkylene-$NR^{A2}R^{A3}$, -C_{0-2} alkylene-3- to 10-membered carbocyclyl, and -C_{0-2} alkylene-4- to 10-membered heterocyclyl;










R^{A2} and R^{A3} are each independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, deuterated C_{1-6} alkyl, deuterated C_{2-6} alkenyl, and deuterated C_{2-6} alkynyl;

R^1 and R^4 are each independently selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, -C_{0-2} alkylene-OR^{11}, -C_{0-2} alkylene-$NR^{11}R^{12}$, -C_{0-2} alkylene- $NR^{11}C(O)R^{12}$, -C_{0-2} alkylene-$C(O)R^{11}$, -C_{0-2} alkylene-$C(O)NR^{11}R^{12}$, -C_{0-2} alkylene-3- to 10-membered carbocyclyl, -C_{0-2} alkylene-4- to 10-membered heterocyclyl, -C_{0-2} alkylene-4- to 10-membered bridged carbocyclyl, -C_{0-2} alkylene-4- to 10-membered bridged heterocyclyl, -C_{0-2} alkylene-5- to 12-membered spiro carbocyclyl, -C_{0-2} alkylene-5- to 12-membered spiro heterocyclyl, -C_{0-2} alkylene-6- to 10-membered aryl, and -C_{0-2} alkylene-5- to 10-membered heteroaryl, wherein the carbocyclyl, heterocyclyl, bridged carbocyclyl, bridged heterocyclyl, spiro carbocyclyl, spiro heterocyclyl, aryl, or heteroaryl is optionally substituted with 1, 2, or 3 R^{13};

R^{11} and R^{12} are each independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, deuterated C_{1-6} alkyl, deuterated C_{2-6} alkenyl, and deuterated C_{2-6} alkynyl;

each R^{13} is independently selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, -C_{0-2} alkylene-OR^{14}, -C_{0-2} alkylene-$NR^{14}R^{15}$, -C_{0-2} alkylene-$NR^{14}C(O)R^{15}$, -C_{0-2} alkylene-$C(O)R^{14}$, and -C_{0-2} alkylene-$C(O)NR^{14}R^{15}$;


R^{14} and R^{15} are each independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, deuterated C_{1-6} alkyl, deuterated C_{2-6} alkenyl, and deuterated C_{2-6} alkynyl;

ring D is selected from , , , , , , , , and ;

R^X is selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, and halogen-substituted C_{2-6} alkynyl;

R^2 is selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, -C_{0-2} alkylene-OR^{21}, -C_{0-2} alkylene-$NR^{21}R^{22}$, -C_{0-2} alkylene-3- to 10-membered carbocyclyl, and -C_{0-2} alkylene-4- to 10-membered heterocyclyl;

R^{21} and R^{22} are each independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, deuterated C_{1-6} alkyl, deuterated C_{2-6} alkenyl, and deuterated C_{2-6} alkynyl;

L is 

, where ring B is attached to Y^5, and ring C is attached to ring D;

ring B is selected from 3- to 10-membered carbocyclyl, 4- to 10-membered heterocyclyl, 4- to 10-membered bridged carbocyclyl, 4- to 10-membered bridged heterocyclyl, 5- to 12-membered spiro carbocyclyl, 5- to 12-membered spiro heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl, wherein the carbocyclyl, heterocyclyl, bridged carbocyclyl, bridged heterocyclyl, spiro carbocyclyl, spiro heterocyclyl, aryl, or heteroaryl is optionally substituted with 1, 2, or 3 R^B;


ring C is selected from 3- to 10-membered carbocyclyl, 4- to 10-membered heterocyclyl, 4- to 10-membered bridged carbocyclyl, 4- to 10-membered bridged heterocyclyl, 5- to 12-membered spiro carbocyclyl, 5- to 12-membered spiro heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl, wherein the carbocyclyl, heterocyclyl, bridged carbocyclyl, bridged heterocyclyl, spiro carbocyclyl, spiro heterocyclyl, aryl, or heteroaryl is optionally substituted with 1, 2, or 3 R^C;


R^B and R^C are each independently selected from hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, -C_{0-2} alkylene-OR^{B1}, and -C_{0-2} alkylene-$NR^{B1}R^{B2}$;


R^{B1} and R^{B2} are each independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, deuterated C_{1-6} alkyl, deuterated C_{2-6} alkenyl, and deuterated C_{2-6} alkynyl;


L^1 is selected from a bond, C_{1-6} alkylene, C_{2-6} alkenylene, and C_{2-6} alkynylene; wherein the carbon atom in the alkylene, alkenylene, or alkynylene is optionally substituted with 1, 2, or 3 heteroatoms, and the alkylene, alkenylene, or alkynylene is optionally substituted with 1, 2, or 3 R^{L1}; and

each R^{L1} is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen-substituted C_{1-6} alkyl, halogen-substituted C_{2-6} alkenyl, halogen-substituted C_{2-6} alkynyl, deuterated C_{1-6} alkyl, deuterated C_{2-6} alkenyl, and deuterated C_{2-6} alkynyl.

2. The compound of claim 1, wherein ring D is .

3. The compound of claim 1, wherein ring D is .

4. The compound of claim 1, wherein ring D is .

5. The compound of claim 1, wherein ring D is .

6. The compound of claim 1, wherein:

Y^1 is N, Y^2 is C, Y^3 is C, Y^4 is CH, Y^5 is N, Y^6 is CH, and Y^7 is CH;





Y^1 is N, Y^2 is C, Y^3 is N, Y^4 is CH, Y^5 is C, Y^6 is CH, and Y^7 is CH;














Y^1 is N, Y^2 is C, Y^3 is N, Y^4 is N, Y^5 is C, Y^6 is CH, and Y^7 is CH;








Y^1 is N, Y^2 is C, Y^3 is N, Y^4 is CH, Y^5 is C, Y^6 is CH, and Y^7 is N; or























Y^1 is N, Y^2 is C, Y^3 is N, Y^4 is CH, Y^5 is C, Y^6 is N, and Y^7 is CH.

7. The compound of claim 1, wherein the compound has one of the following structures:

,
,
,
,






















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













,

,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



,


,

,

,

,

,

,

,

,

,

,

, or

.


8. The compound of claim 1, wherein the compound has one of the following structures:



or

.

9. The compound of claim 1, wherein the compound has one of the following structures:


or

.

10. The compound of claim 1, wherein the compound has one of the following structures:




or



.


11. The compound of claim 1, wherein R^2 is selected from hydrogen, deuterium, halogen, cyano, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxymethyl, trifluoromethyl, difluoromethyl, monofluoromethyl, methoxymethyl, ethoxymethyl, monomethylamino, and dimethylamino.


12. The compound of claim 11, wherein R^2 is selected from hydrogen, fluoro, and methyl.


13. The compound of claim 1, wherein ring A is selected from:





,



,



,



,



,



,


,


,


,



,


, and


, wherein:

















R^{A1} is selected from hydrogen, deuterium, halogen, cyano, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxymethyl, trifluoromethyl, difluoromethyl, monofluoromethyl, methoxymethyl, ethoxymethyl, monomethylamino, and dimethylamino; and



R^{A11} is selected from methyl, ethyl, propyl, cyclopropyl, and halogen-substituted methyl, ethyl, propyl, and cyclopropyl.

14. The compound of claim 13, wherein ring A is 

, and R^{A1} is hydrogen or methyl.






15. The compound of claim 1, wherein R^1 is selected from hydrogen, deuterium, halogen, cyano, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxymethyl, methoxy, ethoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, methoxymethyl, ethoxymethyl, monomethylamino, dimethylamino, deuterated monomethylamino, deuterated dimethylamino,


















,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

.


16. The compound of claim 15, wherein R^1 is selected from methoxy, dimethylamino,

, and

.

17. The compound of claim 1, wherein Q is CH or N.


18. The compound of claim 1, wherein


ring C is selected from

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





19. The compound of claim 1, wherein L has one of the following structures:








,



,



,



,



,


,


,



,



,



, and



, where the aa-end is attached to Y^5, and the bb-end is attached to ring D.

20. A compound selected from:














,


,












,












,












,

,

,

,

,

,

,

,

,

,

,











,











,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,













,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,













,

,


,

,

,

,

,

,

,

,

,

,

,













,

,


,

,

,

,

,

,

,

,

,

,

,

,















,












,


,

,

,

,

,

,

,

,

,

,

,

,

,











,












,

,

,

,

,

,

,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,

,

,

,











,











,












,

,

,

,

,

,

,

,

,

.












,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,













,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,

,








,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

and a stereoisomer or pharmaceutically acceptable salt thereof.

21. The compound of claim 20, wherein the compound is



, or a stereoisomer or pharmaceutically acceptable salt thereof.

22. The compound of claim 20, wherein the compound is


, or a stereoisomer or pharmaceutically acceptable salt


thereof.

23. The compound of claim 20, wherein the compound is




, or a stereoisomer or pharmaceutically acceptable salt thereof.

24. The compound of claim 20, wherein the compound is




, or a stereoisomer or pharmaceutically acceptable salt thereof.

25. The compound of claim 20, wherein the compound is



, or a stereoisomer or pharmaceutically acceptable salt thereof.


26. The compound of claim 20, wherein the compound is



, or a stereoisomer or pharmaceutically acceptable salt


thereof.

27. The compound of claim 20, wherein the compound is




, or a stereoisomer or pharmaceutically acceptable salt thereof.


28. The compound of claim 20, wherein the compound is




, or a stereoisomer or pharmaceutically acceptable salt thereof.


29. The compound of claim 1, wherein ring D is  .


30. The compound of claim 1, wherein the compound has one of the following structures:






or  .

31. The compound of claim 1, wherein the compound has one of the following structures:




or  .

32. The compound of claim 13, wherein ring A is , and R^{A1} is methyl or trifluoromethyl.



33. The compound of claim 1, wherein ring B is  or , and q is 0, 1, 2, or 3.

34. The compound of claim 1, wherein L^1 is selected from a bond, methylene, and ethylene.



35. The compound of claim 1, wherein L has the following structure:

.


36. The compound of claim 1, wherein L has one of the following structures:

 or .

37. The compound of claim 1, wherein L has one of the following structures:

 or .


38. The compound of claim 1, wherein L has the following structure:




39. The compound of claim 1, wherein R^B and R^C are each independently selected from hydrogen, halogen, C_{1-6} alkyl, halogen-substituted C_{1-6} alkyl, -C_{0-2} alkylene-OR^{B1}, and -C_{0-2} alkylene-$NR^{B1}R^{B2}$.

40. The compound of claim 39, wherein R^B is hydrogen, and R^C is hydrogen, fluoro, or methoxy.

41. The compound of claim 1, wherein the compound is of Formula I-a or Formula I-b:



Formula I-a




Formula I-b

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:

V is -C(O)NH- or -NHC(O)-;

T is a bond;

Q is CH or N;



ring A is 

, wherein R^{A1} is hydrogen or C_{1-6} alkyl;


R^1 is selected from -OR^{11}, -$NR^{11}R^{12}$, and 4- to 10-membered heterocyclyl;

R^{11} and R^{12} are each independently selected from hydrogen and C_{1-6} alkyl;

R^2 is selected from hydrogen, halogen, and C_{1-6} alkyl;

L is  or  ; and

R^C is selected from hydrogen, halogen, C_{1-6} alkyl, and -O-C_{1-6} alkyl.

42. The compound of claim 41, wherein ring A is .

43. The compound of claim 41, wherein R^1 is -$NR^{11}R^{12}$.

44. The compound of claim 43, wherein R^1 is dimethylamino.

45. The compound of claim 41, wherein R^2 is selected from hydrogen or fluoro.

46. The compound of claim 41, wherein R^C is selected from hydrogen or fluoro.

47. A pharmaceutically acceptable composition comprising a compound of any one of claims 1 to 46, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

48. Use of a therapeutically effective amount of a compound of any one of claims 1 to 46, or a stereoisomer or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of psoriasis.

49. Use of a therapeutically effective amount of a compound of any one of claims 1 to 46, or a stereoisomer or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of enteritis.

50. Use of a therapeutically effective amount of a compound of any one of claims 1 to 46, or a stereoisomer or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of rheumatoid arthritis.

51. Use of a therapeutically effective amount of a compound of any one of claims 1 to 46, or a stereoisomer or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of idiopathic dermatitis.

52. The compound of any one of claims 1 to 46, or a stereoisomer or pharmaceutically acceptable salt thereof, for use as a medicament.